Mepolizumab exposure and blood eosinophils
Reference paper ↗A coupled subcutaneous or intravenous PK/PD model linking mepolizumab absorption and distribution to concentration-dependent suppression and turnover of circulating eosinophils.
- Therapeutic
- Mepolizumab, Nucala
- Modality
- Monoclonal antibody
- Target
- IL5, IL-5
- Disease
- Eosinophilic asthma
- Model type
- PKPD
Complete model workspace
Checking workspace access…
- Parameters
- 15
- States
- 6
- Equations
- 6
- Derived outputs
- 21
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
12.5 mg SC every 4 weeks, three doses
How do route and dose change mepolizumab exposure and the depth and duration of eosinophil suppression? Explore this intervention regimen through Mepolizumab concentration, Blood eosinophils, Eosinophil inhibition, Cumulative exposure.
Starting result
This result reflects the starting settings. Run your changes to update it.
Result preview could not load
The generated result could not be loaded. The inputs remain available below.
Starting configuration
Time: 0–140 day; step 1
| Input | Default | Available range |
|---|---|---|
| Clearance intravenous | 0.21 L/day | 0.105–0.315 L/day |
| Central distribution volume intravenous | 3.6 L | 1.8–5.4 L |
| Absorption rate constant | 0.194 1/day | 0.097–0.291 1/day |
| Half-maximal inhibitory concentration | 1,261 ng/mL | 630.5–1,892 ng/mL |
| Imax fraction | 0.928 dimensionless | 0.464–1.392 dimensionless |
Expected readouts
Mepolizumab concentration · Blood eosinophil concentration (Gcell/L) · Eosinophil inhibition · Exposure (AUC) (ug*day/mL)
Adjustable model parameters
This public explorer exposes 5 curated parameters. Sign in to edit all 15 declared model parameters.
More key parameters (1)
How the model represents the biology
A coupled subcutaneous or intravenous PK/PD model linking mepolizumab absorption and distribution to concentration-dependent suppression and turnover of circulating eosinophils.
Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.
Model scope: Explicit IL-5 concentration, mepolizumab–IL-5 binding or occupancy, bone-marrow or tissue eosinophil pools, trafficking, asthma symptoms, and clinical response are not represented. IL-5 is therapeutic context only; the runtime applies empirical concentration-dependent inhibition directly to circulating-eosinophil production.
Modeled relationships (7)
- SC or IV regimen → Subcutaneous depot: SC bolus (flow)
- SC or IV regimen → Systemic mepolizumab: IV input (flow)
- Subcutaneous depot → Systemic mepolizumab: Fsc · KA (flow)
- Systemic mepolizumab → Drug clearance: weight-scaled CL (loss)
- Systemic mepolizumab → Eosinophil production: Hill inhibition (modulation)
- Eosinophil production → Blood eosinophils: baseline production (production)
- Blood eosinophils → Eosinophil turnover: KOUT loss (loss)
Modeled relationships: SC or IV regimen to Subcutaneous depot: SC bolus (flow); SC or IV regimen to Systemic mepolizumab: IV input (flow); Subcutaneous depot to Systemic mepolizumab: Fsc · KA (flow); Systemic mepolizumab to Drug clearance: weight-scaled CL (loss); Systemic mepolizumab to Eosinophil production: Hill inhibition (modulation); Eosinophil production to Blood eosinophils: baseline production (production); Blood eosinophils to Eosinophil turnover: KOUT loss (loss).
Primary readouts: Central mepolizumab; Blood eosinophils; Eosinophil inhibition; Cumulative exposure.
Related models
Research use only — not for patient-specific prediction or dosing advice.
